Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Glisoxepide

From Wikipedia, the free encyclopedia
Glisoxepide
Names
Preferred IUPAC name
N-[2-(4-{[(Azepan-1-yl)carbamoyl]sulfamoyl}phenyl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard100.042.329Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27) checkY
    Key: ZKUDBRCEOBOWLF-UHFFFAOYSA-N checkY
  • InChI=1/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
    Key: ZKUDBRCEOBOWLF-UHFFFAOYAG
  • O=C(NCCc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2)c3noc(c3)C
Properties
C20H27N5O5S
Molar mass449.52388 g/mol
Pharmacology
A10BB11 (WHO)
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Chemical compound

Glisoxepide (INN) is an orally availableanti-diabetic drug from the group ofsulfonylureas.[1] It belongs to second-generation sulfonylureas.[2]

References

[edit]
  1. ^Haupt E, Köberich W, Beyer J, Schöffling K (December 1971)."Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects".Diabetologia.7 (6):449–54.doi:10.1007/bf01212061.PMID 5004178.
  2. ^Loubatières, A; Ribes, G; Mariani, MM; Alric, R (1973). "Pharmacological Comparison Between Tolbutamide and Two Second Generation Hypoglycemic Sulfonylureas (Glibenclamide and Glisoxepide)".Acta Diabetologica Latina.10 (2):261–82.doi:10.1007/bf02590661.PMID 4200420.
Oraldiabetes medication,insulins andinsulin analogues, and other drugs used in diabetes (A10)
Fast-acting
Short-acting
Long-acting
Ultra-long-acting
Inhalable
  • Exubera
  • Afrezza
Oral
Non-insulins
Insulin sensitizers
Biguanides
TZDs ("-glitazones") andPPAR agonists
Dual PPAR agonists
Amylin analogues andDACRAs
Secretagogues
K+ATP
Sulfonylureas
Meglitinides ("-glinides")
GLP-1 receptor agonists
GLP1 poly-agonist peptides
DPP-4 inhibitors ("-gliptins")
Other
Aldose reductase inhibitors
Alpha-glucosidase inhibitors
SGLT2 inhibitors ("-gliflozins")
Other
Combinations
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
Stub icon

Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Glisoxepide&oldid=1121639852"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp